publication . Article . 2016

Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE Study

Esther M. John; Esther M. John; Leslie Bernstein; Lene Mellemkjær; Jonine L. Bernstein; Patrick Concannon; Meghan Woods; Kathleen E. Malone; Anne S. Reiner; Rikke Langballe; ...
Open Access
  • Published: 01 Jul 2016 Journal: Breast Cancer Research, volume 18 (eissn: 1465-542X, Copyright policy)
  • Publisher: Springer Science and Business Media LLC
Abstract
Background Treatment with tamoxifen or chemotherapy reduces the risk of contralateral breast cancer (CBC). However, it is uncertain how long the protection lasts and whether the protective effect is modified by patient, tumor, or treatment characteristics. Methods The population-based WECARE Study included 1521 cases with CBC and 2212 age- and year of first diagnosis-matched controls with unilateral breast cancer recruited during two phases in the USA, Canada, and Denmark. Women were diagnosed with a first breast cancer before age 55 years during 1985–2008. Abstraction of medical records provided detailed treatment information, while information on risk factors ...
Subjects
free text keywords: Cancer Research, Oncology, Medicine(all), Research Article, Contralateral breast cancer, Breast cancer, medicine.disease, medicine, Internal medicine, medicine.medical_specialty, Young adult, Risk assessment, Tamoxifen, medicine.drug, Odds ratio, Chemotherapy, medicine.medical_treatment, Cancer, business.industry, business, Surgical oncology
Funded by
NIH| Breast Cancer, Radiation and the ATM-CHEK2 Pathway
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5R01CA114236-02
  • Funding stream: NATIONAL CANCER INSTITUTE
,
NIH| BREAST CANCER, RADIATION EXPOSURE, AND THE ATM GENE
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5U01CA083178-02
  • Funding stream: NATIONAL CANCER INSTITUTE
,
NIH| Interaction of Radiation, BRCA1/2, and Breast Cancer
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5R01CA097397-03
  • Funding stream: NATIONAL CANCER INSTITUTE
,
NIH| MOUSE GENETICS
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 2P30CA008748-43
  • Funding stream: NATIONAL CANCER INSTITUTE
,
NIH| Genome-Wide Association Study of Radiation Exposure and Bilateral Breast Cancer
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5R01CA129639-05
  • Funding stream: NATIONAL CANCER INSTITUTE
24 references, page 1 of 2

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet.. 2005; 365 (9472): 1687-717 [PubMed] [DOI]

Davies, C, Godwin, J, Gray, R, Clarke, M, Cutter, D. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011; 378 (9793): 771-84 [OpenAIRE] [PubMed] [DOI]

Cook, LS, Weiss, NS, Schwartz, SM, White, E, McKnight, B, Moore, DE. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst. 1995; 87 (18): 1359-64 [OpenAIRE] [PubMed] [DOI]

Schaapveld, M, Visser, O, Louwman, WJ, Willemse, PH, de Vries, EG, van der Graaf, WT. The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat. 2008; 110 (1): 189-97 [OpenAIRE] [PubMed] [DOI]

Hooning, MJ, Aleman, BM, Hauptmann, M, Baaijens, MH, Klijn, JG, Noyon, R. Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer. J Clin Oncol. 2008; 26 (34): 5561-8 [OpenAIRE] [PubMed] [DOI]

Bertelsen, L, Bernstein, L, Olsen, JH, Mellemkjaer, L, Haile, RW, Lynch, CF. Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study. J Natl Cancer Inst. 2008; 100 (1): 32-40 [OpenAIRE] [PubMed] [DOI]

Vichapat, V, Garmo, H, Holmqvist, M, Liljegren, G, Warnberg, F, Lambe, M. Tumor stage affects risk and prognosis of contralateral breast cancer: results from a large Swedish-population-based study. J Clin Oncol. 2012; 30 (28): 3478-85 [PubMed] [DOI]

Newcomb, PA, Solomon, C, White, E. Tamoxifen and risk of large bowel cancer in women with breast cancer. Breast Cancer Res Treat. 1999; 53 (3): 271-7 [PubMed] [DOI]

Mellemkjaer, L, Steding-Jessen, M, Frederiksen, K, Andersson, M, Ejlertsen, B, Jensen, MB. Risk of contralateral breast cancer after tamoxifen use among Danish women. Ann Epidemiol. 2014; 24 (11): 843-8 [OpenAIRE] [PubMed] [DOI]

Li, CI, Daling, JR, Porter, PL, Tang, MT, Malone, KE. Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer. Cancer Res. 2009; 69 (17): 6865-70 [OpenAIRE] [PubMed] [DOI]

Xu, L, Zhao, Y, Chen, Z, Wang, Y, Chen, L, Wang, S. Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis. Breast Cancer. 2015

Reding, KW, Bernstein, JL, Langholz, BM, Bernstein, L, Haile, RW, Begg, CB. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer. Breast Cancer Res Treat. 2010; 123 (2): 491-8 [OpenAIRE] [PubMed] [DOI]

Narod, SA, Brunet, JS, Ghadirian, P, Robson, M, Heimdal, K, Neuhausen, SL. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet. 2000; 356 (9245): 1876-81 [PubMed] [DOI]

Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet.. 1998; 351 (9114): 1451-67 [PubMed] [DOI]

O'Regan, R, Jordan, VC, Gradishar, WJ. Tamoxifen and contralateral breast cancer. J Am Coll Surg. 1999; 188 (6): 678-83 [PubMed] [DOI]

24 references, page 1 of 2
Abstract
Background Treatment with tamoxifen or chemotherapy reduces the risk of contralateral breast cancer (CBC). However, it is uncertain how long the protection lasts and whether the protective effect is modified by patient, tumor, or treatment characteristics. Methods The population-based WECARE Study included 1521 cases with CBC and 2212 age- and year of first diagnosis-matched controls with unilateral breast cancer recruited during two phases in the USA, Canada, and Denmark. Women were diagnosed with a first breast cancer before age 55 years during 1985–2008. Abstraction of medical records provided detailed treatment information, while information on risk factors ...
Subjects
free text keywords: Cancer Research, Oncology, Medicine(all), Research Article, Contralateral breast cancer, Breast cancer, medicine.disease, medicine, Internal medicine, medicine.medical_specialty, Young adult, Risk assessment, Tamoxifen, medicine.drug, Odds ratio, Chemotherapy, medicine.medical_treatment, Cancer, business.industry, business, Surgical oncology
Funded by
NIH| Breast Cancer, Radiation and the ATM-CHEK2 Pathway
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5R01CA114236-02
  • Funding stream: NATIONAL CANCER INSTITUTE
,
NIH| BREAST CANCER, RADIATION EXPOSURE, AND THE ATM GENE
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5U01CA083178-02
  • Funding stream: NATIONAL CANCER INSTITUTE
,
NIH| Interaction of Radiation, BRCA1/2, and Breast Cancer
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5R01CA097397-03
  • Funding stream: NATIONAL CANCER INSTITUTE
,
NIH| MOUSE GENETICS
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 2P30CA008748-43
  • Funding stream: NATIONAL CANCER INSTITUTE
,
NIH| Genome-Wide Association Study of Radiation Exposure and Bilateral Breast Cancer
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5R01CA129639-05
  • Funding stream: NATIONAL CANCER INSTITUTE
24 references, page 1 of 2

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet.. 2005; 365 (9472): 1687-717 [PubMed] [DOI]

Davies, C, Godwin, J, Gray, R, Clarke, M, Cutter, D. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011; 378 (9793): 771-84 [OpenAIRE] [PubMed] [DOI]

Cook, LS, Weiss, NS, Schwartz, SM, White, E, McKnight, B, Moore, DE. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst. 1995; 87 (18): 1359-64 [OpenAIRE] [PubMed] [DOI]

Schaapveld, M, Visser, O, Louwman, WJ, Willemse, PH, de Vries, EG, van der Graaf, WT. The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat. 2008; 110 (1): 189-97 [OpenAIRE] [PubMed] [DOI]

Hooning, MJ, Aleman, BM, Hauptmann, M, Baaijens, MH, Klijn, JG, Noyon, R. Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer. J Clin Oncol. 2008; 26 (34): 5561-8 [OpenAIRE] [PubMed] [DOI]

Bertelsen, L, Bernstein, L, Olsen, JH, Mellemkjaer, L, Haile, RW, Lynch, CF. Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study. J Natl Cancer Inst. 2008; 100 (1): 32-40 [OpenAIRE] [PubMed] [DOI]

Vichapat, V, Garmo, H, Holmqvist, M, Liljegren, G, Warnberg, F, Lambe, M. Tumor stage affects risk and prognosis of contralateral breast cancer: results from a large Swedish-population-based study. J Clin Oncol. 2012; 30 (28): 3478-85 [PubMed] [DOI]

Newcomb, PA, Solomon, C, White, E. Tamoxifen and risk of large bowel cancer in women with breast cancer. Breast Cancer Res Treat. 1999; 53 (3): 271-7 [PubMed] [DOI]

Mellemkjaer, L, Steding-Jessen, M, Frederiksen, K, Andersson, M, Ejlertsen, B, Jensen, MB. Risk of contralateral breast cancer after tamoxifen use among Danish women. Ann Epidemiol. 2014; 24 (11): 843-8 [OpenAIRE] [PubMed] [DOI]

Li, CI, Daling, JR, Porter, PL, Tang, MT, Malone, KE. Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer. Cancer Res. 2009; 69 (17): 6865-70 [OpenAIRE] [PubMed] [DOI]

Xu, L, Zhao, Y, Chen, Z, Wang, Y, Chen, L, Wang, S. Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis. Breast Cancer. 2015

Reding, KW, Bernstein, JL, Langholz, BM, Bernstein, L, Haile, RW, Begg, CB. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer. Breast Cancer Res Treat. 2010; 123 (2): 491-8 [OpenAIRE] [PubMed] [DOI]

Narod, SA, Brunet, JS, Ghadirian, P, Robson, M, Heimdal, K, Neuhausen, SL. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet. 2000; 356 (9245): 1876-81 [PubMed] [DOI]

Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet.. 1998; 351 (9114): 1451-67 [PubMed] [DOI]

O'Regan, R, Jordan, VC, Gradishar, WJ. Tamoxifen and contralateral breast cancer. J Am Coll Surg. 1999; 188 (6): 678-83 [PubMed] [DOI]

24 references, page 1 of 2
Any information missing or wrong?Report an Issue